<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851106</url>
  </required_header>
  <id_info>
    <org_study_id>2020-A02679-30</org_study_id>
    <nct_id>NCT04851106</nct_id>
  </id_info>
  <brief_title>Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.</brief_title>
  <acronym>EDEN</acronym>
  <official_title>Evaluation of Endoscopic Ultrasound Shear Wave Elastography (EUS-SWE) for the Diagnosis of Pancreatic Adenocarcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GCS Ramsay Santé pour l'Enseignement et la Recherche</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GCS Ramsay Santé pour l'Enseignement et la Recherche</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the diagnostic accuracy of Shear Wave elastography (SWE) for the diagnosis of&#xD;
      pancreatic adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic adenocarcinoma (PA) is the most common tumor of the pancreas, representing more&#xD;
      than 90% of all solid pancreatic neoplasia and 55% -73% of solid pancreatic masses.&#xD;
&#xD;
      Given its poor prognosis and the major therapeutic consequences, the discrimination between&#xD;
      PA and other pancreatic solid lesions is mandatory. Endoscopic ultrasound (EUS) is admitted&#xD;
      as the most sensitive imaging procedure for the detection and characterization of pancreatic&#xD;
      tumors. Based on only endosonographic features, it remains difficult to differentiate PA from&#xD;
      other solid masses, the specificity (Spe) and accuracy of EUS for the diagnosis of pancreatic&#xD;
      tumor malignancy range from 53-69% and 72-83%, respectively. Over the last 15 years,&#xD;
      endoscopic ultrasound fine needle aspiration (EUS-FNA) or more recently fine needle biopsy&#xD;
      (EUS-FNB) has demonstrated its efficiency for tissue sampling and pathologic diagnosis of PA.&#xD;
      Complementary techniques have been developed to increase the diagnostic performance of EUS.&#xD;
      EUS-Elastography (EUS-E) is another EUS image enhancement technique, which rational based on&#xD;
      the difference in elasticity between the tissues. There are two types of elastographies:&#xD;
      strain elastography (SE) and shear wave elastography (SWE).&#xD;
&#xD;
      Several studies have demonstrated the utility of ultrasound SWE (US-SWE) for the differential&#xD;
      diagnosis of lesions of the breast, thyroid, prostate and for detection of pancreatic&#xD;
      fibrosis and chronic pancreatitis. However, to date, there is no data about the performance&#xD;
      of EUS-SWE for the differential diagnosis of pancreatic solid lesions.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 21, 2021</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The negative predictive value (NPV) determined from shear wave elastography</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>Patient with a solid pancreatic lesion of an undetermined nature</arm_group_label>
    <description>Patient with a solid pancreatic lesion of an undetermined nature</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Endoscopic ultrasound</intervention_name>
    <description>Diagnosis of pancreatic adenocarcinoma with endoscopic ultrasound.</description>
    <arm_group_label>Patient with a solid pancreatic lesion of an undetermined nature</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with a solid pancreatic mass of indeterminate origin&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years of age&#xD;
&#xD;
          -  Patient with a solid pancreatic mass of indeterminate origin&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with ASA score 4 or 5&#xD;
&#xD;
          -  Patient with contraindication to SonoVue injection&#xD;
&#xD;
          -  Protected patient : major under guardianship, tutorship or other legal protection,&#xD;
             deprived of liberty by judicial or administrative decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rodica GINCUL</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpital Jean Mermoz</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rodica GINCUL</last_name>
    <phone>0615340869</phone>
    <email>rodica_h13@yahoo.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hôpital Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rodica Gincul</last_name>
      <phone>0615340869</phone>
      <email>rodica_h13@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Rodica Gincul</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>April 15, 2021</study_first_submitted>
  <study_first_submitted_qc>April 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

